Compare Adaptive Biotechnologies Corp (ADPT) vs Tencent Music Entertainment Group - ADR (TME) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Tencent Music Entertainment Group - ADR — how do they compare? Adaptive Biotechnologies Corp trades at $19.94 (market cap $3.33B), while Tencent Music Entertainment Group - ADR trades at $8.8 (market cap $14.27B). The key difference: Tencent Music Entertainment Group - ADR is far larger — about 4.3× Adaptive Biotechnologies Corp's market cap, and Tencent Music Entertainment Group - ADR pays a 2.78% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | TME | |
|---|---|---|
Market Cap | $3.33B | $14.27B |
Sector | Health | Media |
52-Week High | $22.37 | $26.36 |
52-Week Low | $10.24 | $8.16 |
Enterprise Value | $3.19B | $11.05B |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
TME trades at $8.62, showing slight daily weakness. The stock presents a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company reported strong revenue growth to $32.90B in 2025 with a robust net income margin of 26.48%, though recent quarterly earnings have missed expectations. Analyst sentiment is divided with a consensus price target of $14.00, representing significant upside potential from current levels.
The investment case for TME hinges on its solid profitability and reasonable valuation multiples, but faces headwinds from competitive pressures and recent earnings misses. Key risks include intensifying competition in China's music streaming market and potential regulatory scrutiny. The consensus view suggests moderate bullishness with the stock trading below analyst targets, though execution on growth initiatives remains critical.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Tencent Music Entertainment Group - ADR
TME is the largest online music service provider in China. It was founded in 2016 with the business combination of QQ Music (founded in 2005), Kuwo Music (founded in 2005) and Kugou Music (founded in 2004) streaming platforms. Tencent is the largest shareholder of TME with over 50% shares and over 90% voting rights held. TME also provides social entertainment services, including music live audio/video broadcasts and online concert services through the three platforms mentioned above, and online karaoke through an independent platform WeSing.
Read more on TME →
